Memantine for Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): A Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: Memantine, an NMDA receptor uncompetitive antagonist, is currently approved by the Food and Drug Administration for the treatment of moderate to severe Alzheimer’s disease. Anecdotal reports have suggested that memantine may improve neurological and cognitive symptoms of individuals with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Psychiatry
Main Authors: Seritan, Andreea L., Nguyen, Danh V., Mu, Yi, Tassone, Flora, Bourgeois, James A., Schneider, Andrea, Cogswell, Jennifer, Cook, Kylee, Leehey, Maureen, Grigsby, Jim, Olichney, John M., Adams, Patrick, Legg, Wendi, Zhang, Lin, Hagerman, Paul, Hagerman, Randi J.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296896/
https://ncbi.nlm.nih.gov/pubmed/24345444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4088/JCP.13m08546
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares